



US 20210332140A1

(19) **United States**

(12) **Patent Application Publication**
PERCIER et al.

(10) **Pub. No.: US 2021/0332140 A1**

(43) **Pub. Date: Oct. 28, 2021**

(54) **GALECTIN-10 ANTIBODIES**

(71) Applicants: **argenx BVBA**, Zwijnaarde (BE); **VIB VZW**, Gent (BE); **Universiteit Gent**, Gent (BE)

(72) Inventors: **Jean-Michel PERCIER**, Ixelles (BE); **Christophe BLANCHETOT**, Destelbergen (BE); **Michael SAUNDERS**, Brussel (BE); **Hans DE HAARD**, Oudelande (NL); **Sebastian VAN DER WONING**, Bachte-Maria-Leerne (BE); **Emma PERSSON**, Sint-Andries (BE); **Bart LAMBRECHT**, Gent (BE); **Savvas SAVVIDES**, Kortrijk (BE); **Hamida HAMMAD**, Ronse (BE); **Kenneth VERSTRAETE**, Gent (BE)

(21) Appl. No.: **17/194,950**

(22) Filed: **Mar. 8, 2021**

Related U.S. Application Data

(62) Division of application No. 16/382,997, filed on Apr. 12, 2019, now Pat. No. 11,066,473.

(30) **Foreign Application Priority Data**

Apr. 13, 2018 (GB) 1806099.6
Feb. 6, 2019 (GB) 1901648.4

Publication Classification

(51) **Int. Cl.**
C07K 16/28 (2006.01)
G01N 33/68 (2006.01)
(52) **U.S. Cl.**
CPC **C07K 16/2851** (2013.01); **A61K 2039/505** (2013.01); **G01N 33/68** (2013.01)

(57) **ABSTRACT**

The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Specification includes a Sequence Listing.

